2026-04-13T01:08:13Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/112962025-10-24T10:35:12Zcom_2072_378070com_2072_378040col_2072_378092

Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study Pla, Helena Pardo, Marta Izquierdo Font, Angel Darder Bernabeu, Esther CARBÓ, ANNA Munté, Elisabet Torres-Esquius, Sara Balmaña, Judith Institut Català de la Salut [Pla Juher H, Carbó A] Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Girona, Spain. Precision Oncology Group (OncoGIR-Pro), Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, Spain. Department of Epidemiology and Cancer Register, Girona, Spain. [Pardo M] Precision Oncology Group (OncoGIR-Pro), Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, Spain. [Izquierdo ÀJ] Precision Oncology Group (OncoGIR-Pro), Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, Spain. Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain. Department of Epidemiology and Cancer Register, Girona, Spain. [Darder E] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain. Department of Epidemiology and Cancer Register, Girona, Spain. [Munté E] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, Barcelona, Spain. [Torres Esquius S, Balmaña J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Endometri - Càncer - Epidemiologia Anomalies cromosòmiques Endometri - Càncer - Aspectes genètics Ovariectomia ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Endocrine Surgical Procedures::Castration::Ovariectomy::Salpingo-oophorectomy PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Endometrial Neoplasms Other subheadings::Other subheadings::Other subheadings::/epidemiology TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::procedimientos quirúrgicos endocrinos::castración::ovariectomía::salpingooforectomía FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias endometriales Otros calificadores::Otros calificadores::Otros calificadores::/epidemiología Endometrial cancer; Hysterectomy; Serous carcinoma Càncer d'endometri; Histerectomia; Carcinoma serós Cáncer endometrial; Histerectomía; Carcinoma seroso Objective To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO). Methods The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry. Results After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93–3.95). Conclusions In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors. 2024-04-09T09:52:00Z 2024-04-09T09:52:00Z 2024-04 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Pla-Juher H, Pardo M, Izquierdo ÀJ, Darder E, Carbó A, Munté E, et al. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study. Clin Transl Oncol. 2024 Apr;26:1033–1037. 1699-3055 https://hdl.handle.net/11351/11296 10.1007/s12094-023-03312-4 37682500 001064456600002 http://hdl.handle.net/11351/11296 eng Clinical and Translational Oncology;26 https://doi.org/10.1007/s12094-023-03312-4 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Springer Scientia